Maravai Lifesciences Holdings, Inc. (MRVI)
- Sector
- Life Sciences Tools & Services
- Last price
- $6.53
- As of
Kresmion compiles this page from MRVI's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-07.
See the full MRVI dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for MRVI on one page. Preview it with sample data, then open it live with a free account.
Preview the MRVI dossierActive signals for MRVI
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +209% to MRVI (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +109% to MRVI (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +16613% to MRVI (2026Q2)
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +295% to MRVI (2026Q2)
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 10.7% - EPS $-0.08 vs $-0.0723 estimate
FREE, NO ACCOUNT
Every signal on MRVI, as it fires
You are seeing 5 of 8 signals recorded on MRVI since 2026-05-29.
The five above landed across 2 days. The other 3 were recorded on 1 other days. 4 of the 8 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in MRVI (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 56600D107 · 2026Q2 | $40.6M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 56600D107 · 2026Q2 | $28.7M | 0.04% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 56600D107 · 2026Q2 | $14.1M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 56600D107 · 2026Q2 | $13.2M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 56600D107 · 2026Q2 | $12.5M | 0.01% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, MRVI
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
MRVI against its peers
MRVI's operating margin of -115.9% ranks in the 27th percentile of 23 Life Sciences Tools & Services sub-industry peers, fiscal periods ending between 2025-10-31 and 2026-06-30.
| Metric | MRVI | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 186M USD | 1.2B USD | 29 | 25 |
| Gross margin | 18.3% | 57.4% | 4 | 12 |
| Operating margin | -115.9% | -9.5% | 27 | 23 |
| Net margin | -70.4% | -6.8% | 25 | 25 |
| Return on equity | -61.6% | -7.5% | 14 | 24 |
| P / E | n/a | 45.2x | n/a | 10 |
| 1 year | 97.9% | 26.1% | 79 | 25 |
Peers (25): DNA, MLAB, CTKB, OABI, PACB, FTRE, ABCL, ADPT, SHC, CDXS, BRKR, SEER, TXG, AVTR, RGEN, MXCT, TECH, TEM, CRL, MEDP, MTD, ILMN, WAT, IQV, A. Fiscal periods ending between 2025-10-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (MRVI: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow MRVI on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to MRVI for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.